| NR2F1 controls tumour cell dormancy via SOX9-and RARβ-driven quiescence programmes MS Sosa, F Parikh, AG Maia, Y Estrada, A Bosch, P Bragado, E Ekpin, ... Nature communications 6 (1), 6170, 2015 | 294 | 2015 |
| LuCaP prostate cancer patient‐derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics HM Nguyen, RL Vessella, C Morrissey, LG Brown, IM Coleman, ... The Prostate 77 (6), 654-671, 2017 | 257 | 2017 |
| Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G2 cell … QKY Chan, HM Lam, CF Ng, AYY Lee, ESY Chan, HK Ng, SM Ho, ... Cell Death & Differentiation 17 (9), 1511-1523, 2010 | 255 | 2010 |
| SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer X Zhang, IM Coleman, LG Brown, LD True, L Kollath, JM Lucas, HM Lam, ... Clinical Cancer Research 21 (20), 4698-4708, 2015 | 172 | 2015 |
| Estrogen receptor β2 and β5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion YK Leung, HM Lam, S Wu, D Song, L Levin, L Cheng, CL Wu, SM Ho Endocrine-related cancer 17 (3), 675-689, 2010 | 172 | 2010 |
| A comparative study on aqueous root extracts of Pueraria thomsonii and Pueraria lobata by antioxidant assay and HPLC fingerprint analysis RW Jiang, KM Lau, HM Lam, WS Yam, LK Leung, KL Choi, MMY Waye, ... Journal of Ethnopharmacology 96 (1-2), 133-138, 2005 | 159 | 2005 |
| Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells WY Hu, GB Shi, HM Lam, DP Hu, SM Ho, IC Madueke, A Kajdacsy-Balla, ... Endocrinology 152 (6), 2150-2163, 2011 | 133 | 2011 |
| Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways L Chéry, HM Lam, I Coleman, B Lakely, R Coleman, S Larson, ... Oncotarget 5 (20), 9939, 2014 | 101 | 2014 |
| Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer R Seiler, EA Gibb, NQ Wang, HZ Oo, HM Lam, KE Van Kessel, ... Clinical cancer research 25 (16), 5082-5093, 2019 | 96 | 2019 |
| Estrogen receptor-beta and breast cancer: translating biology into clinical practice YK Leung, MT Lee, HM Lam, P Tarapore, SM Ho Steroids 77 (7), 727-737, 2012 | 89 | 2012 |
| BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1 S Zhu, D Zhao, L Yan, W Jiang, JS Kim, B Gu, Q Liu, R Wang, B Xia, ... Nature communications 9 (1), 500, 2018 | 85 | 2018 |
| Estrogens and prostate cancer: etiology, mediators, prevention, and management SM Ho, MT Lee, HM Lam, YK Leung Endocrinology and Metabolism Clinics 40 (3), 591-614, 2011 | 80 | 2011 |
| Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage P Chatterjee, MT Schweizer, JM Lucas, I Coleman, MD Nyquist, SB Frank, ... The Journal of clinical investigation 129 (10), 4245-4260, 2019 | 76 | 2019 |
| Cellular adhesion promotes prostate cancer cells escape from dormancy N Ruppender, S Larson, B Lakely, L Kollath, L Brown, I Coleman, ... PLoS One 10 (6), e0130565, 2015 | 59 | 2015 |
| Characterizing the molecular features of ERG‐positive tumors in primary and castration resistant prostate cancer MP Roudier, BR Winters, I Coleman, HM Lam, X Zhang, R Coleman, ... The Prostate 76 (9), 810-822, 2016 | 55 | 2016 |
| Durable response of enzalutamide-resistant prostate cancer to supraphysiological testosterone is associated with a multifaceted growth suppression and impaired DNA damage … HM Lam, HM Nguyen, MP Labrecque, LG Brown, IM Coleman, R Gulati, ... European urology 77 (2), 144-155, 2020 | 54 | 2020 |
| Exposure of Human Prostaspheres to Bisphenol A Epigenetically Regulates SNORD Family Noncoding RNAs via Histone Modification SM Ho, A Cheong, HM Lam, WY Hu, GB Shi, X Zhu, J Chen, X Zhang, ... Endocrinology 156 (11), 3984-3995, 2015 | 53 | 2015 |
| Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer HM Lam, B Ouyang, J Chen, J Ying, J Wang, CL Wu, L Jia, M Medvedovic, ... Endocrine-related cancer 21 (6), 903-914, 2014 | 53 | 2014 |
| Hypomethylation of dual specificity phosphatase 22 promoter correlates with duration of service in firefighters and is inducible by low-dose benzo [a] pyrene B Ouyang, CS Baxter, HM Lam, S Yeramaneni, L Levin, E Haynes, S Ho Journal of occupational and environmental medicine 54 (7), 774-780, 2012 | 52 | 2012 |
| Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases M Haider, X Zhang, I Coleman, N Ericson, LD True, HM Lam, LG Brown, ... Clinical & experimental metastasis 33, 239-248, 2016 | 43 | 2016 |
